Redefining Life with CIDP: Marc’s Story of Resilience

In 2019, Marc's life changed dramatically. He was 33 years old, married, a new dad and working full time—there was a lot going on. Amid the chaos of daily life, he noticed something unusual: tingling in his feet. "At first, I thought my shoes were too small," he recalls. "I tried to shrug it off, but then I started to get a weakness in my hands and feet. I couldn't even lift light objects."

One morning while driving to work, Marc lost feeling in his feet. He made it to the emergency room but collapsed upon arrival. "When I finally made it to the doors of the emergency room it was like my body had given up on me," he remembers. Marc was hospitalized for two weeks while his care team worked to determine reason for the sudden change in his health.

Marc's Journey to a CIDP Diagnosis

After he was released from the hospital, Marc experienced a temporary relief in his symptoms before they returned within a few weeks. He became dependent on a walker and reliant on his family's support for everyday tasks, which affected his sense of independence.

"With everything going on, I felt like there was a huge burden on my wife," he recalls. "She took on the role of my care partner, got a new job and completely reworked our approach to nutrition. Our family was also a huge help during this time."

After nearly nine months of recurring hospitalizations, a neurologist diagnosed Marc with chronic inflammatory demyelinating polyneuropathy (CIDP)—a rare neuromuscular disorder that occurs when the immune system mistakenly attacks myelin that surrounds the peripheral nerves. A progressive, relapsing peripheral nervous system disorder, CIDP often causes debilitating symptoms like symmetric weakness or loss of feeling in the arms and legs.

"After receiving my diagnosis, I felt hopeless. Useless. I felt like I couldn't be the husband, dad or person I wanted to be," Marc recalls.

Navigating Treatment Options

Soon after diagnosis, Marc began receiving intravenous immunoglobulin (IVIG) therapy at home to help manage his symptoms. The high volume of immunoglobulin (IG) that Marc required to manage his CIDP symptoms contributed to venous access challenges. One of his veins even collapsed from the high volumes being infused intravenously, so he decided he wanted to try something different that could be easier on his veins. This led him and his health care provider to consider subcutaneous immunoglobulin (SCIG) as an alternative, which can be infused under the skin, instead of intravenously.

While discussing his options with his neurologist, Marc learned about HyQvia^® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], a unique combination of IG and hyaluronidase, also known as a facilitated subcutaneous immunoglobulin treatment, for adults with CIDP.

What is HYQVIA?

HYQVIA is a liquid medicine that is given under the skin (subcutaneously) to treat chronic inflammatory demyelinating polyneuropathy (CIDP) in adults.

IMPORTANT SAFETY INFORMATION

What is the most important information that I should know about HYQVIA?

• HYQVIA can cause blood clots.
• Call your healthcare professional (HCP) if you have pain, swelling, warmth, redness, or a lump in your legs or arms, other than at the infusion site(s), unexplained shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid pulse, numbness or weakness on one side of the body.
• Your HCP may perform blood tests regularly to check your IgG level.
• Do not infuse HYQVIA into or around an infected or red swollen area because it can cause infection to spread.

Please continue reading for additional Important Safety Information.

For Marc, it was important that HyQvia could be infused subcutaneously at home or in an infusion center, and that dosing intervals could be up to once monthly (every two, three or four weeks for adults with CIDP) after a ramp-up period. With appropriate training from his care team, Marc learned how to self-administer HyQvia at home.

Marc infuses in the evenings. He gets everything prepped and then has dinner before doing his infusion on the couch right before bedtime. "Learning to self-infuse was a bit nerve-wracking at first, but now I infuse every three weeks with help from my supportive wife."

Regaining Independence and Focusing on What Matters

Marc found a treatment routine that works for him and decided to return to work full-time. Individual experiences with CIDP and its treatment may vary. Always consult your health care provider for medical advice or services.

"These days, CIDP is no longer the first thing on my mind when I wake up in the morning," he says, remaining focused on enjoying life and time with his family. "I'm committed to being the best father and husband I can be."

To learn more about HyQvia, visit https://www.hyqvia.com.

This content was provided by Takeda. Marc has been compensated by Takeda for sharing his story.

IMPORTANT SAFETY INFORMATION (Continued)

Who should not take HYQVIA?

Do not take HYQVIA if you:

• Are allergic to IgG, hyaluronidase, other blood products, or any ingredient in HYQVIA.

What should I avoid while taking HYQVIA?

• HYQVIA can make vaccines (like measles/mumps/rubella or chickenpox vaccines) not work as well for you. Before you get any vaccines, tell your HCP that you take HYQVIA.

What should I tell my HCP before I start using or while using HYQVIA?

Tell your HCP if you:

• Have or had any kidney, liver, or heart problems or history of blood clots because HYQVIA can make these problems worse.
• Have IgA deficiency or a history of severe allergic reactions to IgG or other blood products.
• Are pregnant, trying to become pregnant or are breast feeding. It is not known whether HYQVIA can harm the unborn baby or breastfed infant.

What are the possible or reasonably likely side effects of HYQVIA?

HYQVIA can cause serious side effects. If any of the following problems occur after starting HYQVIA, stop the infusion immediately and contact your HCP or call emergency services:

• Hives, swelling in the mouth or throat, itching, trouble breathing, wheezing, fainting or dizziness. These could be signs of a serious allergic reaction.
• Bad headache with nausea, vomiting, stiff neck, fever, and sensitivity to light. These could be signs of irritation and swelling of the lining around your brain.
• Reduced urination, sudden weight gain, or swelling in your legs. These could be signs of a kidney problem.
• Pain, swelling, warmth, redness, or a lump in your legs or arms, other than at the infusion site(s). These could be signs of a blood clot.
• Brown or red urine, fast heart rate, yellow skin or eyes. These could be signs of a liver or blood problem.
• Chest pain or trouble breathing, blue lips or extremities. These could be signs of a serious heart or lung problem.
• Fever over 100°F. This could be a sign of an infection.

After HYQVIA infusion a temporary, soft swelling may occur around the infusion site, which may last 1 to 3 days, due to the volume of fluid infused. The following possible side effects may occur at the site of infusion and generally go away within a few hours, and are less likely after the first few infusions.

• Mild or moderate pain
• Redness
• Swelling
• Itching

The most common side effects of HYQVIA are:

• Headache
• Fatigue
• Nausea
• Fever
• Itching
• Redness
• Abdominal pain
• Back pain
• Pain in extremity

Antibodies to the hyaluronidase component of HYQVIA were formed in some patients taking HYQVIA. It is not known if there is any long-term effect. In theory, these antibodies could react with your body's own hyaluronidase (PH20). PH20 is present in the male reproductive tract. So far, these antibodies have not been associated with increased or new side-effects.

These are not all the possible side effects. Talk to your HCP about any side effect that bothers you or that does not go away.

For additional safety information, including Warning about Blood Clots, click for Information For Patients and discuss with your HCP.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://www.fda.gov/medwatch, or call 1-800-FDA-1088.

©2025 Takeda Pharmaceuticals U.S.A., Inc. 500 Kendall Street, Cambridge, MA 02142. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. Takeda and the Takeda Logo are registered trademarks of Takeda Pharmaceutical Company Limited. HyQvia is a registered trademark of Baxalta Incorporated.

US-HYQ-1550v1.0 05/25